[
  {
    "ts": null,
    "headline": "Challenges pharma companies face in push into US manufacturing",
    "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749240997,
      "headline": "Challenges pharma companies face in push into US manufacturing",
      "id": 135082821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d"
    }
  },
  {
    "ts": null,
    "headline": "The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.",
    "summary": "Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.",
    "url": "https://finnhub.io/api/news?id=06b89f264196d37527ecb26d7446e4fc1bba0450f69d3c1d210caea8c6eab5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749240397,
      "headline": "The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.",
      "id": 135082831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.",
      "url": "https://finnhub.io/api/news?id=06b89f264196d37527ecb26d7446e4fc1bba0450f69d3c1d210caea8c6eab5d7"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?",
    "summary": "NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.",
    "url": "https://finnhub.io/api/news?id=89db2cf93168bf950703950f24505c2e740578cf0834eaf02d1c4a7565f65f59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749227880,
      "headline": "Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?",
      "id": 135083537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.",
      "url": "https://finnhub.io/api/news?id=89db2cf93168bf950703950f24505c2e740578cf0834eaf02d1c4a7565f65f59"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749226080,
      "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "id": 135088623,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
    "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
    "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749224369,
      "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
      "id": 135081764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211289162/image_2211289162.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
      "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf"
    }
  },
  {
    "ts": null,
    "headline": "Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls",
    "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded Dollar Tree (DLTR) to Overweight from Neutral with a price target of $111, up from $72, following the post-earnings selloff. The company’s Q1 same-store sales came in above consensus with balanced ticket and traffic composition, the firm tells investors in a research note. Monness Cre",
    "url": "https://finnhub.io/api/news?id=a744e5312b2e751f3c54c3ccc46317c5d6e3f121fad267839994cceb112bdcd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749217241,
      "headline": "Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls",
      "id": 135073948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded Dollar Tree (DLTR) to Overweight from Neutral with a price target of $111, up from $72, following the post-earnings selloff. The company’s Q1 same-store sales came in above consensus with balanced ticket and traffic composition, the firm tells investors in a research note. Monness Cre",
      "url": "https://finnhub.io/api/news?id=a744e5312b2e751f3c54c3ccc46317c5d6e3f121fad267839994cceb112bdcd5"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Novo Nordisk A/S (NVO)?",
    "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses. In a prior call, a viewer asked about Novo Nordisk A/S (NYSE:NVO) as a long-term growth stock. Cramer […]",
    "url": "https://finnhub.io/api/news?id=9f49fdfe9ce8a80aebdb99254ea48713b150bcd99a036504dd39589687406b12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749217179,
      "headline": "Was Jim Cramer Right About Novo Nordisk A/S (NVO)?",
      "id": 135074668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses. In a prior call, a viewer asked about Novo Nordisk A/S (NYSE:NVO) as a long-term growth stock. Cramer […]",
      "url": "https://finnhub.io/api/news?id=9f49fdfe9ce8a80aebdb99254ea48713b150bcd99a036504dd39589687406b12"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Long-Term Growers ETF Q1 2025 Commentary",
    "summary": "During Q1, the Harbor Long Term Growers ETF returned -10.09% (at NAV), underperforming the benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
    "url": "https://finnhub.io/api/news?id=548090960eab348860d22524fe342b17d9572679f102203ea573fcf9d3152656",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749213120,
      "headline": "Harbor Long-Term Growers ETF Q1 2025 Commentary",
      "id": 135080332,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2067714497/image_2067714497.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "During Q1, the Harbor Long Term Growers ETF returned -10.09% (at NAV), underperforming the benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
      "url": "https://finnhub.io/api/news?id=548090960eab348860d22524fe342b17d9572679f102203ea573fcf9d3152656"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Health Care ETF Q1 2025 Commentary",
    "summary": "During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000Â® Growth Health Care Index, which returned 1.99%.",
    "url": "https://finnhub.io/api/news?id=9a9604491941dc839464309d58d454e941b6fdd08d42139f64496692131fdaf0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749208140,
      "headline": "Harbor Health Care ETF Q1 2025 Commentary",
      "id": 135079544,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161777481/image_2161777481.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000Â® Growth Health Care Index, which returned 1.99%.",
      "url": "https://finnhub.io/api/news?id=9a9604491941dc839464309d58d454e941b6fdd08d42139f64496692131fdaf0"
    }
  },
  {
    "ts": null,
    "headline": "Rare Outflow Signals Hit Eli Lilly Shares",
    "summary": "“Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in the way. When great stocks are sale, things are often bleak.",
    "url": "https://finnhub.io/api/news?id=d2d5567b94d2f2a945cb3033af68eb7cbc3139eb588ab701cb41529d96a35509",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749206314,
      "headline": "Rare Outflow Signals Hit Eli Lilly Shares",
      "id": 135080189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "“Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in the way. When great stocks are sale, things are often bleak.",
      "url": "https://finnhub.io/api/news?id=d2d5567b94d2f2a945cb3033af68eb7cbc3139eb588ab701cb41529d96a35509"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock: Is It Still a Smart Buy?",
    "summary": "This one-time weight-loss drug leader has suffered several setbacks lately.  It isn't wise to count out this veteran pharmaceutical company, however.  Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late.",
    "url": "https://finnhub.io/api/news?id=9bedefb269a81fc27e131ce21e70498def3ad068ea5793f975ee0a5ac7f8211e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749199200,
      "headline": "Novo Nordisk Stock: Is It Still a Smart Buy?",
      "id": 135073954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This one-time weight-loss drug leader has suffered several setbacks lately.  It isn't wise to count out this veteran pharmaceutical company, however.  Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late.",
      "url": "https://finnhub.io/api/news?id=9bedefb269a81fc27e131ce21e70498def3ad068ea5793f975ee0a5ac7f8211e"
    }
  },
  {
    "ts": null,
    "headline": "Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says",
    "summary": "The European Medicines Agency'ssafety committee said on Friday Novo Nordisk'spopular weight-loss and diabetes drugs Wegovy and Ozempic may invery rare cases cause a serious eye condition that can...",
    "url": "https://finnhub.io/api/news?id=a6455e53cba47b1b2048fdb7c5fd1fab6909de5f977c966e775cd7521e34a353",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749191059,
      "headline": "Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says",
      "id": 135071632,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The European Medicines Agency'ssafety committee said on Friday Novo Nordisk'spopular weight-loss and diabetes drugs Wegovy and Ozempic may invery rare cases cause a serious eye condition that can...",
      "url": "https://finnhub.io/api/news?id=a6455e53cba47b1b2048fdb7c5fd1fab6909de5f977c966e775cd7521e34a353"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers",
    "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.",
    "url": "https://finnhub.io/api/news?id=5045267787d54bfcd03689a80f2028b728164e1a5d59f321e14e43229d84981f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749180663,
      "headline": "Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers",
      "id": 135073955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.",
      "url": "https://finnhub.io/api/news?id=5045267787d54bfcd03689a80f2028b728164e1a5d59f321e14e43229d84981f"
    }
  },
  {
    "ts": null,
    "headline": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
    "summary": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
    "url": "https://finnhub.io/api/news?id=77a67bf0c113733b93403a0745a49aae374fe4d781ff3028768ff41898a41519",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749173400,
      "headline": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
      "id": 135072336,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
      "url": "https://finnhub.io/api/news?id=77a67bf0c113733b93403a0745a49aae374fe4d781ff3028768ff41898a41519"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY)’s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating",
    "summary": "On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial. TD Cowen’s analysis demonstrates that LLY’s tirzepatide needs to […]",
    "url": "https://finnhub.io/api/news?id=b72941b72469c8fa6c50635fff7b7f178af32e7b55c59fbe73ac49f37cda9433",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749172517,
      "headline": "Eli Lilly (LLY)’s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating",
      "id": 135068010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial. TD Cowen’s analysis demonstrates that LLY’s tirzepatide needs to […]",
      "url": "https://finnhub.io/api/news?id=b72941b72469c8fa6c50635fff7b7f178af32e7b55c59fbe73ac49f37cda9433"
    }
  }
]